文献速递物质与行为成瘾

欧洲与非洲 ancestry 个体阿片使用障碍 GWAS 及多性状分析识别 19 个独立全基因组显著风险位点

Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci.
PubMed 文献 · Mol Psychiatry · 2022-07-25

本研究在欧洲与非洲 ancestry 个体中开展大规模阿片使用障碍(OUD)GWAS,纳入 7 个队列共 N=639,063(Ncases=20,686;Neffective=77,026),并与酒精使用障碍(AUD)和大麻使用障碍(CanUD)进行 MTAG 多性状分析。欧洲 meta 分析识别 3 个全基因组显著先导 SNP,跨 ancestry meta 分析识别 OPRM1 变异,OUD-MTAG 得到 18 个独立全基因组显著位点。OUD-MTAG PRS 解释 3.81% OUD 方差,高于 OUD PRS 的 2.41%。

要点

  • 欧洲 meta 分析识别 FURIN rs11372849 及两个 OPRM1 变异达全基因组显著。
  • 跨 ancestry meta 分析识别 OPRM1 rs1799971 和 rs9478500 达全基因组显著。
  • OUD-MTAG 得到 18 个独立全基因组显著位点,PRS 解释 3.81% OUD 方差。

核心结论

  • 本研究识别 OUD 与 OPRM1 变异关联、FURIN 单变异关联及 OUD-MTAG 中 18 个全基因组显著关联。
  • OUD 遗传架构可能受 OUD 特异性位点与跨物质使用障碍共享位点共同影响。

研究设计与样本

  • 研究纳入 7 个队列:Million Veteran Program、Psychiatric Genomics Consortium、iPSYCH、FinnGen、Partners Biobank、BioVU 和 Yale-Penn 3,总 N=639,063(Ncases=20,686;Neffective=77,026),跨欧洲与非洲 ancestry。
  • OUD 病例定义为终生 OUD 诊断,对照为未知不满足 OUD 标准者。
  • 基于遗传相关性对 OUD、AUD 和 CanUD 进行 MTAG 分析,并在 Yale-Penn 3 中进行留一法 PRS 分析比较 OUD PRS 与 OUD-MTAG PRS 对 OUD 病例状态的预测。

主要发现

  • 欧洲 meta 分析识别 3 个全基因组显著(p ≤ 5 × 10-8)先导 SNP:FURIN rs11372849(p = 9.54 × 10-10)及两个 OPRM1 变异 rs1799971(p = 4.92 × 10-09)和 rs79704991(p = 1.11 × 10-08;r2 = 0.02)。
  • 跨 ancestry meta 分析识别 OPRM1 rs1799971(p = 4.91 × 10-08)和 OPRM1 rs9478500(p = 1.95 × 10-08;r2 = 0.03)。
  • 估计 h2SNP 为 12.75%,与 CanUD 强遗传相关(rg = 0.82;p = 1.14 × 10-47),与 AUD 强遗传相关(rg = 0.77;p = 6.36 × 10-78)。
  • OUD-MTAG 得到 GWAS Nequivalent = 128,748 和 18 个独立全基因组显著位点,部分映射到既往与精神或成瘾表型相关的基因或基因区域。
  • OUD-MTAG PRS 解释 3.81% OUD 方差(beta = 0.61;s.e. = 0.066;p = 2.00 × 10-16),OUD PRS 解释 2.41%(beta = 0.45;s.e. = 0.058;p = 2.90 × 10-13)。

关键数值与推荐

  • 全基因组显著阈值为 p ≤ 5 × 10-8。
  • 欧洲 meta 分析:FURIN rs11372849 p = 9.54 × 10-10;OPRM1 rs1799971 p = 4.92 × 10-09;OPRM1 rs79704991 p = 1.11 × 10-08(r2 = 0.02)。
  • 跨 ancestry meta 分析:OPRM1 rs1799971 p = 4.91 × 10-08;OPRM1 rs9478500 p = 1.95 × 10-08(r2 = 0.03)。
  • h2SNP = 12.75%;rg(OUD-CanUD)= 0.82(p = 1.14 × 10-47);rg(OUD-AUD)= 0.77(p = 6.36 × 10-78)。
  • OUD-MTAG PRS 解释方差 3.81%(beta = 0.61;s.e. = 0.066;p = 2.00 × 10-16)vs OUD PRS 2.41%(beta = 0.45;s.e. = 0.058;p = 2.90 × 10-13)。

临床怎么用

  • OUD-MTAG PRS 在 Yale-Penn 3 中作为 OUD 病例状态预测因子,解释 3.81% OUD 方差,高于 OUD PRS 的 2.41%。
  • OUD 与 AUD、CanUD 存在强遗传相关(rg 分别为 0.77 和 0.82),OUD 遗传架构可能受共享位点影响。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the large toll of opioid use disorder (OUD), genome-wide association studies (GWAS) of OUD to date have yielded few susceptibility loci. We performed a large-scale GWAS of OUD in individuals of European (EUR) and African (AFR) ancestry, optimizing genetic informativeness by performing MTAG (Multi-trait analysis of GWAS) with genetically correlated substance use disorders (SUDs). Meta-analysis included seven cohorts: the Million Veteran Program, Psychiatric Genomics Consortium, iPSYCH, FinnGen, Partners Biobank, BioVU, and Yale-Penn 3, resulting in a total N = 639,063 (Ncases = 20,686;Neffective = 77,026) across ancestries. OUD cases were defined as having a lifetime OUD diagnosis, and controls as anyone not known to meet OUD criteria. We estimated SNP-heritability (h2SNP) and genetic correlations (rg). Based on genetic correlation, we performed MTAG on OUD, alcohol use disorder (AUD), and cannabis use disorder (CanUD). A leave-one-out polygenic risk score (PRS) analysis was performed to compare OUD and OUD-MTAG PRS as predictors of OUD case status in Yale-Penn 3. The EUR meta-analysis identified three genome-wide significant (GWS; p ≤ 5 × 10-8) lead SNPs-one at FURIN (rs11372849; p = 9.54 × 10-10) and two OPRM1 variants (rs1799971, p = 4.92 × 10-09; rs79704991, p = 1.11 × 10-08; r2 = 0.02). Rs1799971 (p = 4.91 × 10-08) and another OPRM1 variant (rs9478500; p = 1.95 × 10-08; r2 = 0.03) were identified in the cross-ancestry meta-analysis. Estimated h2SNP was 12.75%, with strong rg with CanUD (rg = 0.82; p = 1.14 × 10-47) and AUD (rg = 0.77; p = 6.36 × 10-78). The OUD-MTAG resulted in a GWAS Nequivalent = 128,748 and 18 independent GWS loci, some mapping to genes or gene regions that have previously been associated with psychiatric or addiction phenotypes. The OUD-MTAG PRS accounted for 3.81% of OUD variance (beta = 0.61;s.e. = 0.066; p = 2.00 × 10-16) compared to 2.41% (beta = 0.45; s.e. = 0.058; p = 2.90 × 10-13) explained by the OUD PRS. The current study identified OUD variant associations at OPRM1, single variant associations with FURIN, and 18 GWS associations in the OUD-MTAG. The genetic architecture of OUD is likely influenced by both OUD-specific loci and loci shared across SUDs.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Deak JD, Zhou H, Galimberti M, et al. Genome-wide association study in individuals of European and African ancestry and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant risk loci. Mol Psychiatry. 2022. PMID: 35879402. doi:10.1038/s41380-022-01709-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。